Background Extended soft tissue defects of the face are difficult to reconstruct, and autologous
tissue transfers usually lead to poor cosmetic and functional outcomes. We judged that …

Background Transplant recipients in whom cutaneous squamous-cell carcinomas develop
are at high risk for multiple subsequent skin cancers. Whether sirolimus is useful in the …

Background We performed the first human partial face allograft on November 27, 2005.
Here we report outcomes up to 18 months after transplantation. Methods The postsurgical …

Notwithstanding the ongoing coronavirus disease-2019 (Covid-19) pandemic, information
on its clinical presentation and prognosis in recipients of a kidney transplant remain scanty. …

Although cold ischemia time has been widely studied in renal transplantation area, there is
no consensus on its precise relationship with the transplantation outcomes. To study this, we …

Background. Sirolimus, a promising new immunosuppressive drug for organ transplantation,
is currently associated with side effects, such as thrombocytopenia and hyperlipidemia. …

Antibody-mediated rejection (AMR) is a major cause of kidney graft loss, yet assessment of
individual risk at diagnosis is impeded by the lack of a reliable prognosis assay. Here, we …

Background. Sirolimus is an immunosuppressive drug recently developed for organ
transplantation. Its mechanism of action, independent of calcineurin, is different from that of …

Members of the cytokine receptor family are composed of several noncovalently linked chains
with sequence and structure homologies in their extracellular domain. Receptor subfamily …

The level of protection achieved by the standard two doses of COVID-19 mRNA vaccines in
patients receiving maintenance hemodialysis (MHD) remains unclear. To study this we used …